September 2010
Worldwide Biotech;Sep2010, Vol. 22 Issue 9, p1
Trade Publication
The article reports on the licensing of Merrion Pharmaceuticals PLC's facility in Citywest, County Dublin in Ireland under the European Union (EU) Directive for Investigational Medicinal Products. The quality, safety and efficacy of medicines manufactured at the facility were confirmed through inspections conducted by the Irish Medicines Board. Merrion Pharmaceuticals chief executive officer John Lynch discusses the importance of the license for the company, as it permits them to manufacture drugs for clinical trials.


Related Articles

  • Merrion and Rebel Pharmaceuticals Sign Drug Feasibility and Option Agreement.  // BioPharm International;Jan2011, Vol. 24 Issue 1, p13 

    The article reports on the oral drug delivery feasibility and option agreement signed by Merrion Pharmaceuticals Plc and Rebel Pharmaceuticals LLC.

  • Merrion Lands $58M Diabetes Deal with Novo Nordisk. Sheridan, Cormac // BioWorld International;1/21/2009, Vol. 14 Issue 3, p1 

    This article reports on a product development deal entered by Merrion Pharmaceuticals PLC with Novo Nordisk AS in 2009. Under the deal, Merrion is applying its Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology to a series of proprietary glucagon-like...

  • NOVO NORDISK A/S.  // MondayMorning;3/25/2013, Vol. 21 Issue 11, p1 

    The article offers information on the successful completion of the early-stage study of an oral-insulin NN1954 developed by the global healthcare company Novo Nordisk A/S. It mentions that Novo has completed the first of three phases of human testing by using Gastrointestinal Permeation...

  • Other News To Note.  // BioWorld Today;11/24/2010, Vol. 21 Issue 228, p2 

    This section offers news briefs related to the biotechnology industry as of November 24, 2010. Manufacturing of Onsolis at BioDelivery Sciences International Inc. has resumed after Aveva Drug Delivery Systems voluntarily shutdown. The U.S. Food and Drug Administration (FDA) has approved the...

  • Panacea Biotec completes transfer of pharmaceuticals business to wholly owned subsidiary.  // Ace Analyser: Company News;2/6/2020, pN.PAG 

    PBPL obtained the drug manufacturing license on February 1, 2020

  • Clinic Roundup.  // BioWorld Today;11/17/2010, Vol. 21 Issue 223, p2 

    This section offers news briefs on clinical trials. Anthera Pharmaceuticals Inc. has decided to temporarily put on hold its PEARL-SC Phase IIb study of A-623 in systemic lupus erythematosus after it found cracking in clinical product vials. Patient enrollment has started in a Phase 1b trial of...

  • Vectura Inks $31.2M Licensing Deal with GlaxoSmithKline. Moran, Nuala // BioWorld International;8/11/2010, Vol. 15 Issue 32, p1 

    The article reports on a licensing deal reached by Vectura plc with GlaxoSmithKline plc (GSK) in 2010. Vectura intends to close its facility in Nottingham as part of its plans to minimize expenditure in research and development (R&D) by 6 million British pounds on an annual basis. The licensing...

  • phrama in brief.  // Chemical Market Reporter;6/2/2003, Vol. 263 Issue 22, p10 

    Reports on global developments related to the pharmaceutical industry as of June 2, 2003. Plan of ChemPacific Corp. to build a custom chemical manufacturing plant in Shanghai, China; Termination of Eli Lilly and Co.'s development and license agreement for the development and commercialization...

  • pharmaceuticals & fine chemicals.  // Chemical Week;9/20/2006, Vol. 168 Issue 31, p52 

    The article offers news related to the pharmaceutical and fine chemicals industries as of September 20, 2006. An agreement was signed by UCB for a research license to use a high-yield cell line for the efficient manufacture of monoclonal antibodies developed by biotech firm Crucell. A vaccines...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics